Patients with myasthenia gravis (MG) and their healthcare team build strong relationships of trust. No one knows your patients better than you do—so we need your help to enroll eligible patients with MG into a Phase 3 study evaluating the safety and efficacy of subcutaneous rozanolixizumab.
We are at a moment in time when there is much to be done for those affected by MG. As we at UCB strive to advance the understanding of the condition and to work towards new treatment possibilities, we are excited at the possibility that rozanolixizumab could provide a new therapeutic option to patients in need.
"I am very excited about [the] positive results with subcutaneous rozanolixizumab. Today, there is a clear need for safe, effective, non-invasive, non-burdensome therapies for patients with generalized MG, who continue to face serious, potentially life-threatening symptoms associated with their disease."–Dr. Vera Bril, MD Professor at the University of Toronto and principal investigator of rozanolixizumab phase 2 clinical study
MycarinGstudy is an 18-week study that will evaluate the safety and efficacy of rozanolixizumab compared to placebo in patients with generalized myasthenia gravis (gMG). The study, which will enroll around the world, will consist of a screening period (1-28 days), a treatment period (6 weeks) and an observation period (8 weeks).
During the study treatment period, participants will be randomly assigned to receive either the investigational study medication or a placebo. Each study drug dosing will be delivered once per week for six weeks. Study site visits will consist of tests, disease monitoring and subcutaneous infusion of the study drug. Participants are allowed to stay on current therapies they use to manage their MG (as long as they are not taking a medication prohibited by the protocol), and home visits may be an option for some patients.
We encourage an open line of communication between the study site staff and you. And to ensure your patients can still work hand-in-hand with an expert, study participants will receive close and frequent care that only adds to the relationship they already have with you.
Are your patients eligible?
Enrollment is open to those:
Diagnosed with gMG
18 years of age or older
Experiencing mild to severe MG symptoms involving more than just the eyes
Female participants must not be pregnant and must be taking a highly effective form of birth control.
There are additional enrollment criteria. To be eligible to participate in this study, your patients must meet all the inclusion and none of the exclusion criteria at screening, reconfirmed at the baseline visit.
MycarinGstudy is currently enrolling
We are looking to partner with the MG community and their doctors to help evaluate a potential new subcutaneous treatment option.
questions about MycarinGstudy?
If you’ve got questions about the study, we’ve got answers.